Targeted drug approval accelerates the comprehensive requirements for genetic testing
Malignant tumors are one of the main causes of death among residents in China. Among them, the highest mortality rate of lung cancer in malignant tumors has caused serious harm to national health. In fact, a tumor is essentially a genetic disease. If you can accurately know which genes have been mutated, and you can just find drugs that target these gene mutations to inhibit tumor growth or destroy tumor cells, you can achieve precise treatment of tumors. Improve patient survival and give patients a better quality of life. As of the end of 2017, 11 lung cancer targeted drugs have been approved by the FDA/CFDA. Recently, the state has also successively issued a series of measures to accelerate the approval, tariff reduction, and inclusion of medical insurance to effectively improve the accessibility of anticancer drugs. More and more targeted drug selection puts higher demands on the comprehensiveness and accuracy of genetic testing. Yesterday, China's first tumor multi-gene second-generation sequencing test kit was accelerated, and it was officially listed in the top three hospitals and oncology hospitals nationwide. “Diagnosis†and “drugs†go hand in hand, which will better help patients with non-small cell lung cancer. Choose the method of targeted drug therapy.
Accurate diagnosis of second-generation sequencing and one-time detection can understand multi-gene mutation points
The family doctor online edited the kit at the press conference, the kit is based on high-throughput sequencing (NGS) hybrid capture sequencing method for the "human EGFR / ALK / BRAF / KRAS gene mutation combined detection kit (reversible end Termination of sequencing)). Compared with traditional genetic testing methods, patients can simultaneously understand the status of all sensitive mutation sites of multiple tumor treatment-related genes through a second-generation sequencing technology, helping to select the most appropriate treatment.
Professor Wu Yilong of Guangdong Provincial People's Hospital pointed out that with the deepening of tumor precision medicine, clinicians really feel that more genetic information can help to make more appropriate treatment decisions. Second-generation sequencing is a high-throughput gene detection technology that allows parallel detection of multiple tumor-related genes at a time, without missing multiple-driver gene mutations, and covering genetic loci that are not included in traditional assays. This additional information can have a significant impact on treatment decisions. For adenocarcinoma in lung cancer and squamous cell carcinoma patients with smoking habits, genetic mutations are prone to occur. The NGS kit has a great precision diagnosis advantage in the treatment of these patients.
A clear and accurate diagnosis will not only help patients avoid missing the right targeted treatment opportunities, but also help patients who cannot benefit from targeted treatments to reduce economic and time losses. Prof. Wu Yilong lamented: “Before the second-generation sequencing was approved, the traditional detection method required a gene to detect one gene. On the one hand, it was too expensive to consume the patient's valuable tumor tissue samples. On the one hand, some information will be missed. The first tumor II The official approval of the sequencing detection products means that clinicians have more efficient weapons to diagnose patients with more accurate disease and achieve the desired results."
Icebreaking Tour: China's first clinical validation of the second generation sequencing kit for tumors
Second-generation sequencing can provide more useful information for clinicians, but accurate testing requires strict supervision of reagents, environment, processes and personnel. According to family doctors online, only laboratories with molecular testing qualifications have the ability to introduce and implement second-generation sequencing. As the lead unit of the clinical trial of this approval, Professor Liu Weiping, director of the Department of Pathology, West China Hospital of Sichuan University, said: "The approval of the tumor multi-gene second-generation sequencing kit means that the accuracy and stability of this product has been rigorously clinical. The experiment verified that this is the first time that China has completed the clinical verification of the second generation sequencing kit for tumors. In this process, the hospital has accumulated rich experience in the standardized management of the second generation of tumor sequencing technology. In the future, standardization will be formed. The second-generation sequencing technology will inevitably go deep into clinical tumor diagnosis and treatment at a faster pace. Patients can directly test in the hospital, which is easier for the hospital to regulate and manage, and is more convenient and quality-assured for patients."
Hand & Foot Mask,Foot Mask,Dead Skin Removing Foot Mask,Nourishing Tender Foot Mask
Guangzhou Lingxue Cosmetics Co., Ltd , https://www.gzlxgj188.com